Stock Price Forecast

March 26, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Exagen Inc chart...

About the Company

exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.

Sector

Manufacturing

Industry

Dental Laboratories

Employees

231

CEO

Fortunato Rocca

Exchange

NASDAQ

Website

http://www.exagen.com

$48M

Total Revenue

231

Employees

$26M

Market Capitalization

-0.93

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $XGN News

Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Annual Report

7d ago, source:

Exagen Inc. (NASDAQ:XGN) came out with a strong set of annual numbers that could potentially lead to a re-rate of the stock.

Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call Transcript

9d ago, source: InvestingChannel on MSN

March 18, 2024 Exagen Inc.  isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to Exagen Inc.'s Fourth ...

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results

10d ago, source:

CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full ...

Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates

10d ago, source: Zacks.com on MSN

Exagen Inc. (XGN) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.58 per share a year ago. These figures are ...

Exagen’s Strong Q4 Performance and Positive Outlook Justify Buy Rating

9d ago, source:

TD Cowen analyst Daniel Brennan maintained a Buy rating on Exagen (XGN – Research Report) today and set a price target of $7.00. Daniel ...

Exagen reports Q4 results

10d ago, source: Seeking Alpha

Net loss was $5.6 million, compared to a net loss of $14.4 million for the fourth quarter of 2022. Adjusted EBITDA was $(3.9) million for the fourth quarter of 2023 compared to $(13.4) million for the ...

Cresco Labs Inc. (CRLBF) Q4 Earnings and Revenues Surpass Estimates

12d ago, source:

Cresco Labs Inc. (CRLBF) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to loss of $0.03 per share a year ago.

Q4 2023 Exagen Inc Earnings Call

9d ago, source:

Greetings. Welcome to Exagen Inc's fourth-quarter 2023 earnings call. (Operator Instructions) Please note that this conference is being recorded. At this time, I'll hand the conference over to Ryan ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...